Department of Gastroenterology, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Department of Pathology, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Am J Med Sci. 2023 Dec;366(6):430-437. doi: 10.1016/j.amjms.2023.08.014. Epub 2023 Sep 1.
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect the gastrointestinal (GI) tract in coronavirus disease 2019 (COVID-19) patients, the mechanism of GI tract injury is largely unknown. We aimed to study the potential factors that cause COVID-19 GI symptoms.
We investigated the expression and co-localization of angiotensin converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), SARS-CoV-2 nucleocapsid protein (NP), and the severity of inflammation in GI tissues from COVID-19 patients (n = 19) by immunofluorescence and histopathologic staining, and then studied their associations with GI symptoms.
Infected stomach tissues showed significantly higher ACE2 expression than uninfected ones, while infected duodenum tissues showed significantly higher TMPRSS2 expression than uninfected ones. The expression of TMPRSS2 exhibited a moderate correlation with viral NP across different GI tissues, while no significant association was observed between ACE2 and viral NP. Some GI symptoms such as diarrhea and nausea, were related to the expression level of ACE2, TMPRSS2 or the severity of inflammation. Furthermore, age and elevated aspartate transaminase were major risk factors for disease progression.
ACE2 and TMPRSS2 were essential proteins in the SARS-CoV-2 infection of GI tract, while TMPRSS2 rather than ACE2 may play a more important role. GI symptoms may derive from the host receptor expression level and pro-inflammatory response in COVID-19 patients after viral infection of GI tissues, and further exacerbate the disease. So targeting TMPRSS2 and inflammation may represent an effective strategy for treating COVID-19 patients with GI symptoms.
尽管严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)可在 2019 冠状病毒病(COVID-19)患者的胃肠道(GI)中感染,但 GI 道损伤的机制在很大程度上尚不清楚。我们旨在研究导致 COVID-19 GI 症状的潜在因素。
我们通过免疫荧光和组织病理学染色,研究了 COVID-19 患者(n=19)的 GI 组织中血管紧张素转换酶 2(ACE2)、跨膜丝氨酸蛋白酶 2(TMPRSS2)、SARS-CoV-2 核衣壳蛋白(NP)的表达和共定位,以及炎症的严重程度,并研究了它们与 GI 症状的关系。
感染的胃组织 ACE2 表达明显高于未感染的组织,而感染的十二指肠组织 TMPRSS2 表达明显高于未感染的组织。TMPRSS2 的表达与不同 GI 组织中的病毒 NP 呈中度相关,而 ACE2 与病毒 NP 之间无明显相关性。一些 GI 症状,如腹泻和恶心,与 ACE2、TMPRSS2 的表达水平或炎症的严重程度有关。此外,年龄和天冬氨酸转氨酶升高是疾病进展的主要危险因素。
ACE2 和 TMPRSS2 是 SARS-CoV-2 感染 GI 道的必需蛋白,而 TMPRSS2 而不是 ACE2 可能发挥更重要的作用。GI 症状可能源于 COVID-19 患者在病毒感染 GI 组织后宿主受体表达水平和促炎反应,并进一步加重疾病。因此,针对 TMPRSS2 和炎症可能是治疗 COVID-19 伴有 GI 症状患者的有效策略。